bevacizumab + imetelstat + paclitaxel

This is a combination therapy that has been studied in clinical trials, particularly for locally recurrent or metastatic breast cancer. The combination consists of three distinct drugs: 1. **Bevacizumab** - A monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis 2. **Imetelstat** - A telomerase inhibitor that binds to the template RNA strand of telomerase 3. **Paclitaxel** - A taxane-based chemotherapy agent ## Clinical Development The combination has been investigated in phase I and phase II clinical trials. A phase I study evaluated imetelstat in combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic breast cancer[1]. This study aimed to determine the maximally tolerated dose (MTD) and assess preliminary safety and efficacy. In this phase I trial, patients received imetelstat (160-375 mg/m² as a 2-hour IV infusion) on days 1, 8, and 15 of a 28-day cycle, along with paclitaxel and bevacizumab[1]. The study enrolled 14 patients, including 3 with de novo metastatic breast cancer and 6 with prior (neo)adjuvant taxane treatment. ## Efficacy Data The phase I study reported promising efficacy results: - 1 complete response (CR) - 4 partial responses (PRs) - 5 stable disease (SD) - Overall response rate of 38.5% among 13 evaluable patients[1] Other studies of paclitaxel and bevacizumab (without imetelstat) have shown response rates of approximately 55% in metastatic breast cancer patients[2]. ## Safety Profile The most common adverse events observed with this combination therapy were: - Cytopenias (particularly neutropenia and thrombocytopenia) - Grade ≥2 neutropenia occurred in 35.7% of patients, requiring paclitaxel dose reductions - 78.6% of patients experienced dose delays or omissions due to neutropenia and/or thrombocytopenia - Other common grade ≥2 adverse events included lymphopenia, fatigue, nausea/vomiting, diarrhea, chest pain, and rash[1] No dose-limiting toxicities were observed within the initial 28-day treatment cycle in the phase I study. ## Mechanism of Action The combination leverages three distinct mechanisms: 1. Bevacizumab inhibits angiogenesis by targeting VEGF, reducing blood supply to tumors 2. Imetelstat inhibits telomerase, which is required for self-renewal of cancer stem cells 3. Paclitaxel acts as a microtubule stabilizer, disrupting cell division The rationale for this combination includes targeting both the bulk tumor cells (with paclitaxel), tumor vasculature (with bevacizumab), and potential cancer stem cells (with imetelstat)[1]. ## Current Status Based on the search results, this specific three-drug combination has been studied in clinical trials, including a randomized study evaluating imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel alone[3][4][6][7]. However, the current development status and whether this specific combination has progressed to later-phase trials is not clearly indicated in the provided search results.